Compare Stocks: THRD, KURA, ALMS, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$6.14 -6.5%	$14.52	$4.37 ▼ $31.35	$794.05M	-0.38	2.25 million shs	924,738 shs
KURA Kura Oncology	$9.68 -1.5%	$11.39	$7.36 ▼ $13.90	$862.47M	0.47	1.67 million shs	856,284 shs
MLTX MoonLake Immunotherapeutics	$10.33 -0.8%	$13.98	$8.80 ▼ $23.29	$877.91M	1.08	1.52 million shs	834,261 shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.08%	-5.34%	-28.54%	-77.23%	+42.30%
KURA Kura Oncology	-5.48%	-6.65%	-13.70%	-13.24%	-1.01%
MLTX MoonLake Immunotherapeutics	-2.53%	-4.93%	-16.79%	-47.85%	-2.35%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$6.14 -6.5%	$14.52	$4.37 ▼ $31.35	$794.05M	-0.38	2.25 million shs	924,738 shs
KURA Kura Oncology	$9.68 -1.5%	$11.39	$7.36 ▼ $13.90	$862.47M	0.47	1.67 million shs	856,284 shs
MLTX MoonLake Immunotherapeutics	$10.33 -0.8%	$13.98	$8.80 ▼ $23.29	$877.91M	1.08	1.52 million shs	834,261 shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.08%	-5.34%	-28.54%	-77.23%	+42.30%
KURA Kura Oncology	-5.48%	-6.65%	-13.70%	-13.24%	-1.01%
MLTX MoonLake Immunotherapeutics	-2.53%	-4.93%	-16.79%	-47.85%	-2.35%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.86	Moderate Buy	$33.27	441.37% Upside
KURA Kura Oncology	2.77	Moderate Buy	$25.35	164.37% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	181.07% Upside
THRD Third Harmonic Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest THRD, KURA, ALMS, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/14/2026	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/5/2026	ALMS Alumis	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	KURA Kura Oncology	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$50.00
10/2/2026	ALMS Alumis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/1/2026	KURA Kura Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$30.00
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	33.08	N/A	N/A	$2.88 per share	2.13
KURA Kura Oncology	$67.48M	12.64	N/A	N/A	$2.00 per share	4.80
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	$6.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
THRD Third Harmonic Bio	-$45.47M	-$0.62	N/A	N/A	N/A	N/A	-19.27%	-18.67%	N/A

Latest THRD, KURA, ALMS, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$23.81 million	N/A
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
KURA Kura Oncology	0.12	4.73	4.71
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
THRD Third Harmonic Bio	N/A	54.10	54.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
KURA Kura Oncology	N/A
MLTX MoonLake Immunotherapeutics	93.85%
THRD Third Harmonic Bio	93.95%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
KURA Kura Oncology	7.60%
MLTX MoonLake Immunotherapeutics	10.40%
THRD Third Harmonic Bio	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
THRD Third Harmonic Bio	N/A	45.13 million	41.61 million	No Data

THRD, KURA, ALMS, and MLTX Headlines

Recent News About These Companies

THRD Share News Today

June 25, 2026 | uk.investing.com

Third Harmonic Bio to Delist from Nasdaq

July 31, 2025 | tipranks.com

Third Harmonic Bio, Inc. (THRD) Cash Flow - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Third Harmonic Bio Stock (NASDAQ:THRD), Insider Trading Activity

July 11, 2025 | benzinga.com

Third Harmonic Bio Inc News (THRD) - Investing.com

July 3, 2025 | investing.com

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

June 12, 2025 | globenewswire.com

Northeast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State Stands

June 9, 2025 | msn.com

Third Harmonic Bio plans to liquidate the company, sell urticaria treatment

April 14, 2025 | msn.com

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered

April 14, 2025 | msn.com

Third Harmonic Bio Announces Plan of Liquidation and Dissolution

April 14, 2025 | globenewswire.com

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

March 27, 2025 | globenewswire.com

Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 4, 2025 | zacks.com

Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?

February 14, 2025 | zacks.com

Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)

February 14, 2025 | zacks.com

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

February 11, 2025 | globenewswire.com

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

November 25, 2024 | globenewswire.com

Apple making foray into smart home IP camera market, says analyst Ming-Chi Kuo

November 13, 2024 | finance.yahoo.com

Updates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROs

November 12, 2024 | jdsupra.com

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade

November 11, 2024 | zacks.com

(LEAD) Netmarble swings to black in Q3 on steady-selling titles

November 8, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, KURA, ALMS, and MLTX Company Descriptions

Alumis NASDAQ:ALMS

$6.14 -0.43 (-6.48%)

As of 01:45 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Kura Oncology NASDAQ:KURA

$9.68 -0.15 (-1.51%)

As of 01:45 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.33 -0.08 (-0.79%)

As of 01:45 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Third Harmonic Bio NASDAQ:THRD

TF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, KURA, ALMS, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, KURA, ALMS, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, KURA, ALMS, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, KURA, ALMS, and MLTX Company Descriptions

Alumis NASDAQ:ALMS

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, KURA, ALMS, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, KURA, ALMS, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, KURA, ALMS, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, KURA, ALMS, and MLTX Company Descriptions

Alumis NASDAQ:ALMS

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools